$4.62
-0.24 (-4.94%)
Open$4.86
Previous Close$4.86
Day High$4.96
Day Low$4.57
52W High$5.08
52W Low$1.19
Volume—
Avg Volume1.06M
Market Cap296.20M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+849.1% upside
Current
$4.62
$4.62
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 149.50M | 150.30M | 19.43M |
| Net Income | -74,619,441 | -67,515,328 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -65,670,160 | -62,719,063 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |